1286794-22-6

Basic information

• Product Name: 6(R)-[5-(trifluoromethyl)-2-pyridyl]-5R-(2,4,6-trifluorophenyl)-5,6-dihydro-N,N-bis[(4-methoxyphenyl)methyl]-2,5-dimethyl-2H-1,2,4-thiadiazin-3-amine-1,1-dioxide
• Synonyms: 6(R)-[5-(trifluoromethyl)-2-pyridyl]-5R-(2,4,6-trifluorophenyl)-5,6-dihydro-N,N-bis[(4-methoxyphenyl)methyl]-2,5-dimethyl-2H-1,2,4-thiadiazin-3-amine-1,1-dioxide
• CAS NO: 1286794-22-6
• Molecular Weight: 692.682
• Mol File: 1286794-22-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 6(R)-[5-(trifluoromethyl)-2-pyridyl]-5R-(2,4,6-trifluorophenyl)-5,6-dihydro-N,N-bis[(4-methoxyphenyl)methyl]-2,5-dimethyl-2H-1,2,4-thiadiazin-3-amine-1,1-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 6(R)-[5-(trifluoromethyl)-2-pyridyl]-5R-(2,4,6-trifluorophenyl)-5,6-dihydro-N,N-bis[(4-methoxyphenyl)methyl]-2,5-dimethyl-2H-1,2,4-thiadiazin-3-amine-1,1-dioxide(1286794-22-6)
• EPA Substance Registry System: 6(R)-[5-(trifluoromethyl)-2-pyridyl]-5R-(2,4,6-trifluorophenyl)-5,6-dihydro-N,N-bis[(4-methoxyphenyl)methyl]-2,5-dimethyl-2H-1,2,4-thiadiazin-3-amine-1,1-dioxide(1286794-22-6)

Safety Data

• Hazardous Substances Data: 1286794-22-6(Hazardous Substances Data)

Upstream product

• 1286794-47-5 5R-(2,4,6-trifluorophenyl)-5,6-dihydro-N,N-bis[(4-methoxyphenyl)methyl]-2,5-dimethyl-2H-1,2,4-thiadiazin-3-amine-1,1-dioxide 
• 69045-82-5 2-fluoro-5-(trifluoromethyl)pyridine 

Relevant articles and documents

IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (a) and include tautomers, solvates, prodrugs, esters, and deuterates thereof, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, ring C, m, n, p, q, -L1-, -L2-,L3-, and L4 - is selected independently and as defined herein. The compounds of the invention have, surprisingly and advantageously, improved solution stability. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Abeta) protein, including Alzheimers Disease, are also disclosed